A c-Met Inhibitor Suppresses Osteosarcoma Progression via the ERK1/2 Pathway in Human Osteosarcoma Cells
Weijie Chen,Su Wu,Yang Huang,Tingting Zhang,Hao Dong,Xing Zheng,Tao Chen,Xiaokang Gong,Gang Liu,Xing Zhao
DOI: https://doi.org/10.2147/ott.s317122
IF: 4
2021-09-10
OncoTargets and Therapy
Abstract:Weijie Chen, 1– 3, &ast Su Wu, 4, &ast Yang Huang, 3, &ast Tingting Zhang, 5 Hao Dong, 6 Xing Zheng, 3 Tao Chen, 3 Xiaokang Gong, 3 Gang Liu, 1, 2 Xing Zhao 1 1 Department of Orthopaedic Surgery, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, HangZhou, People's Republic of China; 2 Key Laboratory of Musculoskeletal System Degeneration and Regeneration Translational Research of Zhejiang Province, HangZhou, People's Republic of China; 3 Department of Orthopedics, Taizhou Municipal Hospital, Taizhou, People's Republic of China; 4 Department of Orthopedics, The Third People's Hospital of JingDeZhen, JingDeZhen, People's Republic of China; 5 Taizhou Public Security Supervision Hospital, Taizhou Municipal Hospital, Taizhou, People's Republic of China; 6 Department of Gastrointestinal Surgery, Taizhou Municipal Hospital, Taizhou, People's Republic of China &astThese authors contributed equally to this work Correspondence: Xing Zhao Email Gang Liu Email Introduction: Osteosarcoma is the most common primary malignancy of the bone among adolescents and children. Despite intensive chemotherapy and aggressive surgery, the 5-year survival rate of osteosarcoma still falls under 70%, mainly due to its tendency to metastasize and to develop drug resistance. Therefore, new treatments for osteosarcoma are urgently needed. HGF/c-Met signaling pathway, when dysregulated, is involved in the onset, progression and metastasis of various cancers, making the HGF/c-Met axis a promising therapeutic target. Methods: In this study, we found Met to be a cancer-promoting gene in osteosarcoma as well, and aimed to investigate the role of a c-met inhibitor (PHA-665752) in osteosarcoma. For this purpose, two human osteosarcoma cell lines (143B and U2OS) were introduced in this study and treated with PHA-665752. CCK8 cell proliferation assay was performed to obtain the IC 50 value of PHA-665752 for 143B and U2OS. After that, colony formation assay, transwell migration and invasion assay and wound-healing assay were performed. Furthermore, a tumor-transplanted mouse model was used for in vivo experiments. Results: Our results showed that PHA-665752 could suppress osteosarcoma progression, promote apoptosis and inhibit proliferation of human osteosarcoma cells. Moreover, we found ERK1/2 pathway to be an important mediator underlying the osteosarcoma-suppressing function of PHA-665752. LY3214996, a highly selective inhibitor of the ERK1/2 pathway, was able to antagonize the effects of PHA-665752 in osteosarcoma. Finally, in vivo experiments indicated that PHA-665752 suppressed tumor growth in a tumor-transplanted mouse model. Conclusion: Taken together, Met provided a druggable target for osteosarcoma and PHA-665752 is a promising candidate for anti-osteosarcoma treatments. Keywords: osteosarcoma, Met, PHA-665752, ERK signaling, LY3214996 Graphical Osteosarcoma (OS) originates from primitive bone-forming mesenchymal stem cells and represents the most common primary bone malignancy in children and adolescents. 1,2 Before the 1970s, amputation surgery was the main treatment for osteosarcoma due to the lack of effective chemotherapy. However, surgeries pose a negative impact on the quality of life, and displayed a limited efficacy with more than 80% of the patients still dying of lung metastasis. 3 In the past 30 years, with the advent of advanced medical methods such as neoadjuvant chemotherapy, the overall 5-year survival rate of osteosarcoma has increased from 20% to 70%. 4 The four basic drugs for osteosarcoma chemotherapy are methotrexate, cisplatin, doxorubicin and ifosfamide. High-dose methotrexate (HDMtx) therapy, such as MAP (methotrexate, doxorubicin, and cisplatin) has become the standard treatment in North America and Europe. 5 However, for those with metastasis or drug resistance, the efficacy of chemotherapy is limited with an overall 5-year survival rate less than 20%. 6,7 Therefore, novel treatments are urgently needed, especially against the emergence of drug resistance and effective for distant metastasis. Hepatocyte growth factor (HGF) and its high-affinity receptor, mesenchymal epithelial transition factor (c-Met) serves multiple functions in embryonic development, 8 organogenesis 9 and wound healing. 10 Previous studies also found that the physiological function of HGF/c-Met axis revolves around cell motility and invasive growth, and displayed a higher activity in many cancers. 11–14</ -Abstract Truncated-
oncology,biotechnology & applied microbiology